Go Deep
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -25,504 | -5.8 | -4.54 | -3.68 | 768.54 |
| Oct 2026 | -25,489 | -5.8 | -4.53 | -3.68 | 764.33 |
| Oct 2026 | -25,468 | -5.7 | -4.51 | -3.68 | 761.59 |
| Oct 2026 | -25,300 | -5.6 | -4.38 | -3.68 | 737.83 |
| Oct 2026 | -25,504 | -5.8 | -4.54 | -3.68 | 765.17 |
| Oct 2026 | -25,409 | -5.7 | -4.47 | -3.68 | 752.84 |
| Oct 2026 | -25,271 | -5.5 | -4.36 | -3.68 | 733.01 |
| Oct 2026 | -25,293 | -5.6 | -4.38 | -3.68 | 734.36 |
BioCryst Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 218,250,000.0 | 156,413,000.0 | 406,555,000.0 | 159,395,000.0 |
| Net Profit | 78,395,000.0 | -721,812,000.0 | 245,845,000.0 | 12,899,000.0 |
| EPS | 0.3 | -3.0 | 1.2 | 0.1 |
BioCryst Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 874,837,000.0 | 450,712,000.0 | 331,412,000.0 | 270,827,000.0 | — |
| Net Profit | 263,861,000.0 | -88,881,000.0 | -226,539,000.0 | -247,116,000.0 | — |
| EPS | 1.3 | -0.4 | -1.2 | -1.3 | — |
BioCryst Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 514,158,000.0 | 490,420,000.0 | 516,960,000.0 | 550,000,000.0 | — |
| Total Liabilities | 633,311,000.0 | 966,354,000.0 | 972,488,000.0 | 844,597,000.0 | — |
| Total Equity | -119,153,000.0 | -475,934,000.0 | -455,528,000.0 | -294,597,000.0 | — |
Owes vs Owns
BioCryst Pharmaceuticals, Inc. owed $1.81 for every $1 it owned in Jun 2026, up from $1.54 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.81× | 1.23× | 1.97× | 1.88× | 1.54× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
BioCryst Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 53.4%Receivables 20.8%Inventory 1.0%Fixed assets (tangible) 3.7%Long-term investments 11.9%Other assets 9.1%
How it's funded — Dec 2025
Long-term debt 67.5%Payables 2.5%Other liabilities 29.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 274.7 | 320.9 | 389.0 | 424.3 |
| Receivables | 106.8 | 79.1 | 57.0 | 50.6 |
| Inventory | 5.4 | 8.1 | 28.7 | 27.5 |
| Fixed assets (tangible) | 19.0 | 19.8 | 20.9 | 8.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 61.2 | 20.3 | 0.0 | 18.1 |
| Other assets | 47.0 | 42.3 | 21.4 | 20.9 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 2.8 | 2.6 | 2.4 |
| Long-term debt | 427.2 | 795.9 | 811.3 | 733.3 |
| Payables | 15.8 | 11.6 | 20.9 | 14.4 |
| Other liabilities | 188.6 | 156.0 | 137.7 | 94.6 |
| Shareholders' equity | -119.2 | -475.9 | -455.5 | -294.6 |
| Net tangible assets | -119.2 | -475.9 | -455.5 | -294.6 |
BioCryst Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 347,369,000.0 | -52,020,000.0 | -95,141,000.0 | -161,850,000.0 | — |
| Investing Activities | -13,694,000.0 | 52,593,000.0 | -131,498,000.0 | -128,238,000.0 | — |
| Financing Activities | -349,931,000.0 | -5,761,000.0 | 32,485,000.0 | 88,027,000.0 | — |